F2R and myeloproliferative neoplasm: Subsequently, the molecular profile of MPN cells was examined after specifically targeting thrombin induced PAR1 activation with PAR1 antagonist (vorapaxar), a synthetic tricyclic 3-phenylpyridine analog derived from natural product himbacine [33].